Clinical Trial Update: Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated long-acting low-dose ropeginterferon in patients with chronic myeloid leukemia who are treated with bosutinib from diagnosis; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Bosutinib (bosutinib)
• Ropeginterferon alfa-2b (ropeginterferon alfa-2b)

Snippet

Sponsor: St. Olavs Hospital | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED